Fundz

Korsana Biosciences completes a private placement closing, raising $380 million led by Fairmount and Venrock Healthcare Capital Partners to fund operations into 2029.

PUBLIC · KRSASep 08, 2026

Amount Raised

$380 Million

Round Type

Post-IPO Equity

WalthamBiotechnologyHealthcareHealth CareTherapeutics

Investors

Janus Henderson InvestorsVivo CapitalGeneral AtlanticTcgxForbionWellington ManagementCommodore CapitalRA Capital ManagementRTW InvestmentsForesite CapitalJ.P. Morgan Life Sciences Private CapitalSR OneSanofi VenturesKalehua CapitalSpruce Street CapitalFairmountVenrock Healthcare Capital Partners

Description

Korsana Biosciences announced the completion of a $380 million private financing from new and existing investors before its merger with Cyclerion Therapeutics. This funding is expected to support multiple clinical milestones for KRSA-028 and ensure financial stability into 2029. Shares will begin trading on Nasdaq under the ticker symbol “KRSA” on September 9, 2026.

Who to call at Korsana Biosciences, and when

A new round usually means Korsana Biosciences is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Korsana Biosciences raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Korsana Biosciences, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Korsana Biosciences. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Korsana Biosciences

Location

Waltham, Massachusetts, United States

About

Korsana Biosciences, Inc. is a biotechnology company focused on discovering and developing novel therapies for neurodegenerative diseases, particularly Alzheimer's disease. The company leverages its proprietary THETA™ therapeutic targeting platform to improve drug delivery and efficacy. Founded in 2024, Korsana aims to elevate patient care by creating potentially best-in-class therapeutics. The company's lead program, KRSA-028, targets amyloid beta and demonstrates strong preclinical data.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Korsana Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

5 contacts
Verified contactsJuan P., Head of Financial Planning & Analysis hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Korsana Biosciences's next move

See what Strategic adds

Korsana Biosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.